ISTITUTO ONCOLOGICO VENETO
🇮🇹Italy
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
Phase 3
Active, not recruiting
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 474
- Registration Number
- NCT02926196
- Locations
- 🇮🇹
Ospedale di Bergamo, Bergamo, BG, Italy
🇮🇹Policlinico Sant'Orsola Malpighi, Bologna, BO, Italy
🇮🇹Ospedale di Bellaria, Bologna, BO, Italy
TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 5
- Registration Number
- NCT02608411
- Locations
- 🇮🇹
Istituto Oncologico Veneto, Padova, Italy
Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients
Phase 3
Completed
- Conditions
- Breast Cancer Metastatic
- Interventions
- Drug: Aromatase Inhibitors
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 110
- Registration Number
- NCT02511639
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, AN, Italy
🇮🇹ASL Brindisi "Antonio Perrini", Brindisi, BR, Italy
🇮🇹Ospedale Papa Giovanni XXIII, Bergamo, Bg, Italy
Videoscopic Ilioinguinal Lymphadenectomy for Melanoma
Not Applicable
Completed
- Conditions
- MelanomaSecondary Malignant Neoplasm of Lymph Node
- Interventions
- Procedure: Videoscopic ilioinguinal dissection
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 23
- Registration Number
- NCT02508909
Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 64
- Registration Number
- NCT02411344
- Locations
- 🇮🇹
Policlinico Vittorio Emanuele, Catania, CT, Italy
🇮🇹A. O. U. Santa Maria della Misericordia, Udine, UD, Italy
🇮🇹Istituto Europeo di Oncologia, Milano, MI, Italy
Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
Completed
- Conditions
- Advanced Non Small Cell Lung Cancer
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 215
- Registration Number
- NCT02407327
- Locations
- 🇮🇹
Istituto Oncologico Veneto, Padova, PD, Italy
Totally Implantable Venous Access Devices: Quality of Life and Body Image
Not Applicable
Completed
- Conditions
- Neoplasms Undergoing Chemotherapy
- Interventions
- Behavioral: psychological support (interactive/cognitive strategies)
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 128
- Registration Number
- NCT02075580
- Locations
- 🇮🇹
Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
Psychological Counselling in Diagnostic Screening
Not Applicable
Completed
- Conditions
- Cancer
- Interventions
- Behavioral: Psychoeducative training
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2013-12-23
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 43
- Registration Number
- NCT02018471
Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients
Phase 2
Completed
- Conditions
- Oral MucositisHead-and-neck Squamous Cell Carcinoma
- Interventions
- Drug: SAMITAL®Drug: Placebo sachets
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 120
- Registration Number
- NCT01941992
- Locations
- 🇮🇹
Radiotherapy Department, Istituto Oncologico Veneto, Padova, Italy
Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
- Conditions
- Metastatic Melanoma
- Interventions
- Drug: Anti-B-RAF
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 200
- Registration Number
- NCT01878396
- Locations
- 🇮🇹
Vanna Chiarion-Sileni, MD, Padova, PD, Italy
© Copyright 2025. All Rights Reserved by MedPath